莱卡奈单抗可延缓阿尔茨海默病：希望与挑战 - Suppr

Lecanemab slows Alzheimer's disease: hope and challenges.

作者信息

Mead Simon, Fox Nick C

机构信息

MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.

Dementia Research Centre, Department of Neurodegenerative Disease, and the UK Dementia Research Institute, UCL Queen Square Institute of Neurology, London WC1N 3AR, UK.

出版信息

Lancet Neurol. 2023 Feb;22(2):106-108. doi: 10.1016/S1474-4422(22)00529-4.

DOI:10.1016/S1474-4422(22)00529-4

PMID:36681438

Abstract

摘要

相似文献

Lecanemab slows Alzheimer's disease: hope and challenges.

Lancet Neurol. 2023 Feb;22(2):106-108. doi: 10.1016/S1474-4422(22)00529-4.

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.

Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839.

Lecanemab in Early Alzheimer's Disease.

N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.

The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.

Neurol Sci. 2024 Aug;45(8):3583-3597. doi: 10.1007/s10072-024-07477-w. Epub 2024 Apr 3.

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.

J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.

Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.

Profiling lecanemab as a treatment option for Alzheimer's disease.

Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3.

[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation].

Brain Nerve. 2024 Sep;76(9):1005-1009. doi: 10.11477/mf.1416202725.

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.

Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.

引用本文的文献

Human Trace Elements, Gut Microbiota, and Alzheimer's Disease: Insights From Multistage Mendelian Randomization Analysis.

Food Sci Nutr. 2025 Aug 12;13(8):e70706. doi: 10.1002/fsn3.70706. eCollection 2025 Aug.

Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged -amyloid nanoscavenger for Alzheimer's disease therapy.

Acta Pharm Sin B. 2025 Jun;15(6):2884-2899. doi: 10.1016/j.apsb.2025.02.035. Epub 2025 Mar 1.

Research Progress in the Molecular Mechanism of NLRP3 Inflammasome in Alzheimer's Disease and Regulation by Natural Plant Products.

Mol Neurobiol. 2025 Jun;62(6):7296-7312. doi: 10.1007/s12035-025-04715-w. Epub 2025 Jan 28.

Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysis.

Alzheimers Dement. 2025 Jan;21(1):e14375. doi: 10.1002/alz.14375. Epub 2024 Dec 23.

The aged female rhesus macaque as a translational model for human menopause and hormone therapy.

Horm Behav. 2024 Nov;166:105658. doi: 10.1016/j.yhbeh.2024.105658. Epub 2024 Nov 11.

Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs).

Brain Sci. 2024 Sep 29;14(10):990. doi: 10.3390/brainsci14100990.

Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis.

Alzheimers Dement. 2024 Dec;20(12):8673-8683. doi: 10.1002/alz.14314. Epub 2024 Oct 22.

Screening of [F]Florbetazine for Aβ Plaques and a Head-to-Head Comparison Study with [C]Pittsburgh Compound-B ([C]PiB) in Human Subjects.

ACS Pharmacol Transl Sci. 2024 Jun 25;7(7):2054-2062. doi: 10.1021/acsptsci.4c00149. eCollection 2024 Jul 12.

Associations of sugar intake, high-sugar dietary pattern, and the risk of dementia: a prospective cohort study of 210,832 participants.

BMC Med. 2024 Jul 18;22(1):298. doi: 10.1186/s12916-024-03525-6.

The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.

Sci Rep. 2024 Jun 20;14(1):14266. doi: 10.1038/s41598-024-65264-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Lecanemab slows Alzheimer's disease: hope and challenges.

作者信息

Mead Simon, Fox Nick C

机构信息

MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.

Dementia Research Centre, Department of Neurodegenerative Disease, and the UK Dementia Research Institute, UCL Queen Square Institute of Neurology, London WC1N 3AR, UK.

出版信息

Lancet Neurol. 2023 Feb;22(2):106-108. doi: 10.1016/S1474-4422(22)00529-4.

DOI:10.1016/S1474-4422(22)00529-4

PMID:36681438

Abstract

摘要

相似文献

Lecanemab slows Alzheimer's disease: hope and challenges.

Lancet Neurol. 2023 Feb;22(2):106-108. doi: 10.1016/S1474-4422(22)00529-4.

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.

Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839.

Lecanemab in Early Alzheimer's Disease.

N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.

The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.

Neurol Sci. 2024 Aug;45(8):3583-3597. doi: 10.1007/s10072-024-07477-w. Epub 2024 Apr 3.

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.

J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.

Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.

Profiling lecanemab as a treatment option for Alzheimer's disease.

Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3.

[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation].

Brain Nerve. 2024 Sep;76(9):1005-1009. doi: 10.11477/mf.1416202725.

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.

Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.

引用本文的文献

Human Trace Elements, Gut Microbiota, and Alzheimer's Disease: Insights From Multistage Mendelian Randomization Analysis.

Food Sci Nutr. 2025 Aug 12;13(8):e70706. doi: 10.1002/fsn3.70706. eCollection 2025 Aug.

Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged -amyloid nanoscavenger for Alzheimer's disease therapy.

Acta Pharm Sin B. 2025 Jun;15(6):2884-2899. doi: 10.1016/j.apsb.2025.02.035. Epub 2025 Mar 1.

Research Progress in the Molecular Mechanism of NLRP3 Inflammasome in Alzheimer's Disease and Regulation by Natural Plant Products.

Mol Neurobiol. 2025 Jun;62(6):7296-7312. doi: 10.1007/s12035-025-04715-w. Epub 2025 Jan 28.

Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysis.

Alzheimers Dement. 2025 Jan;21(1):e14375. doi: 10.1002/alz.14375. Epub 2024 Dec 23.

The aged female rhesus macaque as a translational model for human menopause and hormone therapy.

Horm Behav. 2024 Nov;166:105658. doi: 10.1016/j.yhbeh.2024.105658. Epub 2024 Nov 11.

Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs).

Brain Sci. 2024 Sep 29;14(10):990. doi: 10.3390/brainsci14100990.

Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis.

Alzheimers Dement. 2024 Dec;20(12):8673-8683. doi: 10.1002/alz.14314. Epub 2024 Oct 22.

Screening of [F]Florbetazine for Aβ Plaques and a Head-to-Head Comparison Study with [C]Pittsburgh Compound-B ([C]PiB) in Human Subjects.

ACS Pharmacol Transl Sci. 2024 Jun 25;7(7):2054-2062. doi: 10.1021/acsptsci.4c00149. eCollection 2024 Jul 12.

Associations of sugar intake, high-sugar dietary pattern, and the risk of dementia: a prospective cohort study of 210,832 participants.

BMC Med. 2024 Jul 18;22(1):298. doi: 10.1186/s12916-024-03525-6.

The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.

Sci Rep. 2024 Jun 20;14(1):14266. doi: 10.1038/s41598-024-65264-1.

Lecanemab slows Alzheimer's disease: hope and challenges.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Lecanemab slows Alzheimer's disease: hope and challenges.

作者信息

机构信息

出版信息

相似文献

引用本文的文献